TKThomas Klöss

Thomas Klöss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Klöss has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer

    by Werner Kneist, Michael Ghadimi, Norbert Runkel, Thomas Moesta, Stephan Coerper, Claudia Benecke, Daniel W. Kauff, Stephan Gretschel, Ines Gockel, Boris Jansen-Winkeln, et al.

    Objective: This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer. Background: High-level evidence from clinical trials is required to clarify the benefits of pIONM. Methods: NEUROS was a 2-arm, randomized, controlled, multicenter clinical trial that included 189 patients with rectal cancer who underwent TMEs at 8 centers, from February 2013 to January 2017. TMEs were performed with pIONM (n=90) or without it (control, n=99). The groups were stratified according to neoadjuvant chemoradiotherapy and sex, with blocks of variable length. Data were analyzed according to a modified intention-to-treat protocol. The primary endpoint was a urinary function at 12 months after surgery, assessed with the International Prostate Symptom Score, a patient-reported outcome measure. Deterioration was defined as an increase of at least 5 points from the preoperative score. Secondary endpoints were sexual and anorectal functional outcomes, safety, and TME quality. Results: The intention-to-treat analysis included 171 patients. Marked urinary deterioration occurred in 22/171 (13%) patients, with significantly different incidence between groups (pIONM: n=6/82, 8%; control: n=16/89, 19%; 95% confidence interval, 12.4–94.4; P=0.0382). pIONM was associated with better sexual and ano-(neo)rectal function. At least 1 serious adverse event occurred in 36/88 (41%) in the pIONM group and 53/99 (54%) in the control group, none associated with the study treatment. The groups had similar TME quality, surgery times, intraoperative complication incidence, and postoperative mortality. Conclusion: pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.


  • Entwicklung medizinischer Fachabteilungen – Change Management unter Kostendruck

    by Stefan Ruhl, Thomas Klöss

    Im Klinikalltag ist das Thema Change Management meistens angesiedelt im Spannungsfeld zwischen harten Rationalisierungsvorhaben, die stark am unmittelbaren betriebswirtschaftlichen Erfolg orientiert sind und wachstumsorientierten Projekten, die sich mehr auf Veränderung der Kultur oder auf Erneuerung und Innovation konzentrieren. Oft sind diese widersprüchlichen Dynamiken im Projekt zu vereinen [1]. Dies liegt u. a. darin begründet, dass kurzfristige Rationalisierungsmaßnahmen über nachhaltige Kultur- und Organisationsveränderungen in den Kliniken abgesichert werden müssen, damit ein dauerhafter Erfolg der Abteilung sichergestellt werden kann. Ist dies nicht der Fall, folgt Rationalisierung auf Rationalisierung, da das Unternehmen nicht gelernt hat, sich wachstumsorientiert auszurichten. Wie der Balanceakt zwischen konsequenten Einschnitten und neuem Wachstum gestaltet werden kann, zeigt das folgende Praxisbeispiel.